Filana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update

Article summary

Filana Therapeutics, Inc. released its financial results for the third quarter of 2026, reporting cash and cash equivalents of $47.0 million and research and development expenses of $3.9 million.